Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.

Ciccia, Francesco

Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. [electronic resource] - Rheumatology (Oxford, England) Jul 2014 - 1313-20 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1462-0332

10.1093/rheumatology/keu004 doi


Adult
Aged
Antibodies, Monoclonal, Murine-Derived--pharmacology
Antirheumatic Agents--pharmacology
Apoptosis--drug effects
Female
Humans
In Vitro Techniques
Interferons
Interleukin-17--metabolism
Interleukin-23--metabolism
Interleukins--metabolism
Male
Mast Cells--drug effects
Middle Aged
Rituximab
STAT3 Transcription Factor
Salivary Glands--drug effects
Signal Transduction--drug effects
Sjogren's Syndrome--drug therapy
Th17 Cells--drug effects
Treatment Outcome